Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced that Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to imsidolimab for treating generalized pustular psoriasis (GPP).

The status offers R&D subsidies and potential up to 10 years of market exclusivity in Japan, following similar recognition in the United States.

Positive

• Japan orphan drug designation for imsidolimab in generalized pustular psoriasis
• Potential for up to 10 years of market exclusivity in Japan after approval
• Access to subsidies for research and development costs in Japan
• Regulatory recognition in both Japan and the United States for imsidolimab in GPP

Negative

• None.

News Market Reaction – VNDA

+3.86%

2 alerts

+3.86% Session close to close

$392.68M Market Cap

0.2x Rel. Volume

In the May 27 session, VNDA gained 3.86%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a meaningful regulatory milestone: Japan’s MHLW granted orphan drug designati...

Analysis

This announcement adds a meaningful regulatory milestone: Japan’s MHLW granted orphan drug designation to imsidolimab for GPP, a disease affecting about 2,200 people locally and eligible for up to 10 years market exclusivity. It builds on prior U.S. progress, including BLA acceptance with a PDUFA date, and reinforces the asset’s global potential. Investors may watch for Japanese development timelines, partnering strategy, and any future use of the $200,000,000 shelf to support commercialization.

Key Figures

GPP patients in Japan: 2,200 people Market exclusivity: Up to 10 years GPP cohort size: 1516 patients

3 metrics

GPP patients in Japan 2,200 people Estimated diagnosed generalized pustular psoriasis population in Japan

Market exclusivity Up to 10 years Potential orphan drug market exclusivity in Japan post-approval

GPP cohort size 1516 patients Nationwide inpatient database cohort for GPP outcomes in Japan

Previous Clinical trial Reports

5 past events · Latest: Apr 08 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 08	Phase 2 trial start	Positive	+0.6%	Initiation of Thetis Phase 2 study for NEREUS in GLP-1 patients.
Jan 08	FDA decision setback	Negative	-14.1%	FDA said HETLIOZ sNDA for jet lag cannot be approved as filed.
Nov 05	Conference participation	Neutral	-0.7%	Participation in Stifel 2025 Healthcare Conference investor event.
Oct 08	Brand partnership deal	Positive	+2.7%	Multi-year founding partner and arena branding deal with sports group.
Oct 01	Regulatory framework	Positive	+1.2%	Collaborative FDA framework to resolve disputes on HETLIOZ and tradipitant.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical and regulatory updates have historically produced mixed but mostly modest price moves, with large drops tied to negative FDA outcomes.

Recent Company History

Over the last six months, Vanda’s clinical and regulatory news has ranged from trial initiations to FDA setbacks and collaboration frameworks. Notably, a negative FDA decision on a HETLIOZ sNDA on Jan 8, 2026 coincided with a -14.05% move, while positive steps like a collaborative FDA framework on Oct 1, 2025 and a major sports sponsorship on Oct 8, 2025 saw smaller gains. Today’s Japan orphan designation adds another incremental, globally focused regulatory milestone to this sequence.

Key Terms

orphan drug designation, monoclonal antibody, immunoglobulin G4 (IgG4), interleukin‑36 (IL‑36), +2 more

6 terms

orphan drug designation regulatory

"MHLW has granted orphan drug designation to imsidolimab..."

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

monoclonal antibody medical

"a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody..."

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

immunoglobulin G4 (IgG4) medical

"a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody..."

A subclass of antibody found in blood and tissues that acts like a specialized security unit in the immune system, helping the body recognize and respond to certain threats. Elevated or abnormal IgG4 levels can indicate specific immune conditions or be a target for diagnostic tests and therapies, so changes in IgG4 readings can affect clinical trial outcomes, regulatory decisions and market demand for diagnostic kits and drugs.

interleukin‑36 (IL‑36) medical

"Imsidolimab inhibits interleukin‑36 (IL‑36) receptor signaling..."

Interleukin-36 (IL-36) is a small signaling protein produced by cells that acts like a neighborhood alarm, telling the immune system to start or amplify inflammation. It matters to investors because drugs or tests that block, measure, or modify IL-36 activity can change the course of inflammatory and autoimmune conditions; success or failure in clinical trials, regulatory approval, or adoption of such therapies directly affects the valuation and risk of companies developing those products.

generalized pustular psoriasis medical

"for the treatment of generalized pustular psoriasis (GPP)."

A rare, severe form of psoriasis that causes sudden, widespread patches of pus-filled bumps, intense redness and peeling skin, often with fever and other body-wide symptoms; it can require hospitalization and can be life-threatening. Investors should care because the condition drives demand for specialized therapies, influences clinical trial urgency and regulatory attention, and can affect market size and pricing potential for drugs targeting this high-need patient group—like a small but high-impact niche in healthcare.

market exclusivity regulatory

"potential for up to 10 years of market exclusivity following approval."

Market exclusivity is a limited legal protection that prevents rivals from selling the same drug or product for a set time, even if others could otherwise make a copy. It’s like a temporary shop window reserved for one seller, giving that company sole access to customers for that product. For investors, exclusivity can mean predictable sales and higher profit margins during the protected period, and the impending end of exclusivity is a key risk factor.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).

Imsidolimab inhibits interleukin‑36 (IL‑36) receptor signaling, addressing the deficiency in the endogenous IL‑36 receptor antagonist regulator that is commonly observed in patients with GPP.¹

The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need. In Japan, approximately 2,200 people have been diagnosed with GPP.²  IL36RN genetic variants—which are associated with dysregulation of the IL‑36 pathway—are enriched in the Japanese population, including well‑characterized founder families in Hokkaido.³

In Japan, orphan drug designation provides development incentives, including subsidies for research and development costs, as well as the potential for up to 10 years of market exclusivity following approval.

This designation follows similar regulatory recognition in the United States and underscores the global interest in the potential of imsidolimab to address the significant unmet medical needs of patients with GPP, a rare and severe inflammatory skin disease associated with systemic complications and increased mortality.⁴

References

1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026). 
2. Ministry of Health Labour and Welfare (MHLW), "Pustular psoriasis (generalized type) (Designated Intractable Disease 37)," Japan Intractable Diseases Information Center. Accessed: Mar. 10, 2026. [Online]. Available: https://www.nanbyou.or.jp/entry/168
3. H. Fujita, R. Iwasaki, S. Tsuboi, Y. Murashiuma, and M. Akiyama, "Regional differences in the prevalence of generalized pustular psoriasis in Japan," J. Dermatol., vol. 51, no. 3, pp. 380–390, Mar. 2024, doi: 10.1111/1346-8138.17089.
4. H. Miyachi et al., "Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan," J. Am. Acad. Dermatol., vol. 86, no. 6, pp. 1266–1274, Jun. 2022, doi: 10.1016/j.jaad.2021.06.008.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to, statements regarding the therapeutic potential of imsidolimab for patients with GPP and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are "forward‑looking statements" within the meaning of the securities laws. All statements other than statements of historical fact are statements that could be deemed forward‑looking statements. Forward‑looking statements are based on current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's ability to obtain regulatory approval of, and to successfully commercialize, imsidolimab for the treatment of GPP and Vanda's ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward‑looking statements in this press release should be evaluated together with the risks and uncertainties described in the sections titled "Cautionary Note Regarding Forward‑Looking Statements," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Vanda's most recent Annual Report on Form 10‑K, as updated by Vanda's subsequent Quarterly Reports on Form 10‑Q, Current Reports on Form 8‑K, and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All forward‑looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth herein. Vanda cautions investors not to place undue reliance on forward‑looking statements. The information contained in this press release is provided as of the date hereof, and Vanda undertakes no obligation, and expressly disclaims any obligation, to update or revise any forward‑looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Corporate Contact:

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis-302782517.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did Vanda Pharmaceuticals (NASDAQ: VNDA) announce about imsidolimab in Japan on May 27, 2026?

Vanda Pharmaceuticals announced that Japan's MHLW granted orphan drug designation to imsidolimab for generalized pustular psoriasis (GPP). According to Vanda, this designation supports development of imsidolimab for a rare, severe inflammatory skin disease with significant unmet medical need in Japan.

What benefits does Japan's orphan drug designation provide for Vanda's imsidolimab (VNDA)?

Japan's orphan drug designation provides development incentives for imsidolimab, including subsidies and potential long-term market exclusivity. According to Vanda, designated medicines may receive support for research and development costs and up to 10 years of market exclusivity in Japan following regulatory approval.

How many patients in Japan could benefit from Vanda's imsidolimab for generalized pustular psoriasis?

Approximately 2,200 people in Japan have been diagnosed with generalized pustular psoriasis. According to Vanda, IL36RN genetic variants associated with IL-36 pathway dysregulation are enriched in the Japanese population, highlighting a defined but rare patient group for imsidolimab development.

How does Vanda's imsidolimab work in treating generalized pustular psoriasis (VNDA)?

Imsidolimab is a high-affinity humanized IgG4 monoclonal antibody that inhibits interleukin-36 receptor signaling. According to Vanda, this mechanism targets deficiency in the endogenous IL-36 receptor antagonist regulator, which is commonly observed in patients with generalized pustular psoriasis.

What is the significance of Vanda's imsidolimab receiving orphan drug designation in both Japan and the United States?

Receiving orphan drug recognition in both Japan and the United States highlights broad regulatory interest in imsidolimab. According to Vanda, this supports its potential to address significant unmet medical needs in generalized pustular psoriasis, a rare, severe inflammatory skin disease with systemic complications.

What market exclusivity could Vanda Pharmaceuticals (VNDA) gain in Japan with imsidolimab?

Vanda could obtain up to 10 years of market exclusivity in Japan for imsidolimab after approval. According to Vanda, this exclusivity is part of the incentives linked to orphan drug designation, alongside subsidies for research and development activities in Japan.